source
- Cigna to End Coverage of GLP-1 Weight-Loss Drugs Wegovy and Zepbound for Employees Starting July 1Cigna announced it will stop covering GLP-1 weight-loss medications for its employee health plan, effective July 1. The decision affects drugs such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepboun…
- Eli Lilly signs up to $1.9B deal with Ascidian Therapeutics for RNA editing in kidney diseaseAscidian Therapeutics recently presented early data indicating that its novel RNA‑editing approach to repair faulty genes appears safe in humans, focusing on kidney disease applications. Eli Lilly…